China OKs 601 Drugs for 2026 Medical Insurance Review
China's NHSA announces 601 drugs passed formal review for the 2026 medical insurance catalog, with a 91% pass rate and expanded access for patients.
Tag
10 articles
China's NHSA announces 601 drugs passed formal review for the 2026 medical insurance catalog, with a 91% pass rate and expanded access for patients.
China's NHSA launches a 'Find Medicine' digital feature, helping insured patients locate medications covered by insurance nationwide.
China's NHSA launches a nationwide drug price comparison mini-program across all 31 provinces, helping patients compare prices and reduce medication costs.
China launches cross-province medical insurance account sharing, allowing 300M+ migrant workers to share funds with family nationwide.
China's NHSA reveals four new pharmacy fraud cases in Qinghai and Guangxi, using big data to detect returned drug sales and substitution schemes.
China launches cross-province medical insurance personal account sharing, allowing funds to be used by close relatives nationwide.
China's NHSA launches 2026 dual catalog adjustment for medical and commercial insurance, introducing pre-application mechanisms and expanded eligibility.
China's NHSA will release the first national Basic Medical Insurance Service Directory in Q4 2026, standardizing coverage for 11 categories.
China's NHSA exposes six pharmacy cases involving medical insurance fraud, including drug swapping, empty swiping, and reselling returned drugs.
China's medical insurance fund spent 61.26 billion yuan on special case reviews in 2025, covering 2.07 million complex medical cases under DRG reform.